Two recent studies have supported these findings with one reporting that obese T2DM human subjects following the MD for 210 days exhibited statistically significant elevations in fasting GLP-1 levels with lower serum glucose [167], and with the other showing similar increases in GLP-1 and improved insulin sensitivity [168]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.